Roche, Hansoh Announce Cancer Drug Deal With Over $15 Billion in Potential Milestones

Roche and Hansoh Pharmaceutical Group Co., Ltd. announced a second cancer drug collaboration Oct. 19, covering experimental antibody-drug conjugates and offering Hansoh more than $15 billion in potential milestones. Hansoh will receive $400 million upfront and another $110 million on the collaboration’s first anniversary. The potential milestones are tied to development, regulatory approvals and commercialization. Hansoh may also receive royalties on potential future sales. The portfolio includes two Hansoh programs in preclinical development and several more aimed at targets proposed by Roche. All use antibody-drug conjugate technology. Hansoh retains rights in mainland China, Hong Kong, Macau and Taiwan.

Source: TokenPost